SGLT2 inhibitor dapagliflozin protects the kidney in a murine model of Balkan nephropathy
Yuji Oe, Young Chul Kim, Viktoriya S. Sidorenko, Haiyan Zhang, Sadhana Kanoo, Natalia Lopez, Helen Goodluck, Maria Crespo-Masip, Volker Vallon
Abstract
Recurrent exposure to aristolochic acid (AA) causes kidney function loss and fibrosis in mice and in humans, e.g., in the form of the endemic Balkan nephropathy. Inhibitors of the proximal tubule sodium-glucose transporter SGLT2 can protect against CKD progression, but their effect on AA-induced kidney injury remains unknown. Here we provide the first evidence in a murine model that pretreatment with an SGLT2 inhibitor can attenuate the AA-induced DNA damage response and subsequent nephropathy.
Topics & Concepts
Aristolochic acidKidneyKidney diseaseRenal functionCreatinineDapagliflozinAcute kidney injuryInternal medicineNephropathyEndocrinologyHypertensive NephropathyMedicineFibrosisChemistryPharmacologyDiabetic nephropathyBiologyDiabetes mellitusGeneticsType 2 diabetesNephrotoxicity and Medicinal PlantsTrace Elements in HealthRenal Diseases and Glomerulopathies